NDASUBLINGUALFILM
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
KYNMOBI (apomorphine hydrochloride) by Sumitomo Dainippon Pharma is non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine d4 receptor, and moderate affinity for the dopamine d2, d3, and d5, and adrenergic α1d, α2b, α2c receptors. First approved in 2020.
Drug data last refreshed 7h ago · AI intelligence enriched 9h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYNMOBI is an apomorphine hydrochloride sublingual film approved in May 2020 for Parkinson's disease. It is a non-ergoline dopamine agonist with high binding affinity for the D4 receptor and moderate affinity for D2, D3, D5, and adrenergic receptors. The drug works by stimulating post-synaptic dopamine D2-type receptors in the brain to manage motor symptoms in Parkinson's patients.
$0.002BPart D
Peak9.6 years to LOEProduct is in peak lifecycle phase with modest Part D penetration (~1K claims in 2023), suggesting a niche commercial footprint and lean commercial team structure.
Mechanism of Action
non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D4 receptor, and moderate affinity for the dopamine D2, D3, and D5, and adrenergic α1D, α2B, α2C receptors. The precise mechanism of action of ONAPGO as a treatment for Parkinson's disease is unknown, although it is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KYNMOBI is a niche, peak-stage Parkinson's product with minimal current job openings and modest market penetration, indicating a lean team environment and specialist-focused roles. Career development opportunities are likely concentrated in commercial execution, market access, and medical affairs rather than expansion or innovation.
Brand Manager
Worked on KYNMOBI at Sumitomo Dainippon Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.